RTW Biotech Opportunities Ltd

RTWG

GG00BKTRRM22

Closed End Funds

Market Closed - London S.E. Other stock markets 11:35:16 2024-04-26 am EDT			5-day change	1st Jan Change
1.31 ^USD	-1.13%		+1.16%	-6.60%

Apr. 05	RTW Biotech invests in cell and gene therapy company Obsidian	AN
Apr. 02	EARNINGS: EPE Special "cautiously optimistic"; RTW Biotech NAV rises	AN

RTW Biotech Opportunities NAV increases 2.5% in January

February 14, 2024 at 02:54 pm EST

RTW Biotech Opportunities Ltd - London-based venture capital firm focused on biotechnology companies - Says net asset value per share at January 31 was USD1.94, up 2.5% from USD1.90 the previous month. Notes that this NAV does not reflect the completion of the Arix Bioscience PLC transaction. RTW intends to publish, at the soonest opportunity, an indicative and estimated pro forma NAV and NAV per share reflecting the completion of the transaction and new share issuance. In January, RTW said it completed its previously announced acquisition of a 25.5% stake in Arix Bioscience PLC for USD57.1 million, equivalent to GBP1.37 per Arix share. Purchase is to support its planned all-share acquisition of Arix's assets.

Current stock price: 99.30 pence

12-month change: down 5.6%

By Jeremy Cutler, Alliance News reporter

Comments and questions to newsroom@alliancenews.com

Latest news about RTW Biotech Opportunities Ltd

RTW Biotech invests in cell and gene therapy company Obsidian	Apr. 05	AN
EARNINGS: EPE Special "cautiously optimistic"; RTW Biotech NAV rises	Apr. 02	AN
RTW Biotech Opportunities Ltd Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 28	CI
Franchise Brands sets targets, Cindrigo agrees loan	Feb. 20	AN
RTW Biotech Opportunities NAV increases 2.5% in January	Feb. 14	AN
RTW Biotech Opportunities Completes Arix Bioscience Acquisition	Feb. 13	MT
Katoro Gold launches fundraising, eyes board shake-up	Feb. 12	AN
Arix Bioscience's Asset Sale to RTW Biotech Takes Effect	Feb. 12	MT
Arix Bioscience shares suspended ahead of RTW takeover	Feb. 12	AN
Arix Bioscience Shares to be Suspended on London Exchange Amid Acquisition	Feb. 12	MT
Apax opts against lifting offer; DCI enters loan deal	Feb. 09	AN
Arix Bioscience Shareholders Approve Asset Sale to RTW Biotech	Jan. 29	MT
Arix Bioscience Gains UK Regulatory Approval for Sale to RTW Biotech	Jan. 23	MT
RTW Biotech completes Arix investment in takeover run-up	Jan. 22	AN
RTW Biotech Buys Minority Stake in Arix Bioscience to Support Planned Takeover	Jan. 22	MT
RTW Biotech's manager invests USD127 million in Ji Xing	Jan. 11	AN
RTW Biotech Opportunities invests USD127 million in investee Ji Xing	Jan. 08	AN
Microsaic in funding talks; Jarvis says no payout	Nov. 14	AN
FTSE 100 Closes Up 0.28% as Interest Rate Rise Fears Start to Ease	Nov. 01	DJ
RTW Biotech agrees "immediately accretive" Arix Bioscience takeover	Nov. 01	AN
RTW Biotech Opportunities, Arix Bioscience Agree on Potential Merger Terms	Nov. 01	MT
Transcript : RTW Biotech Opportunities Ltd, Arix Bioscience plc - Pre Recorded M&A Call	Oct. 31
Brandshield shareholders approve AIM delisting	23-10-13	AN
RTW Biotech's Rocket Pharmaceuticals makes Danon progress	23-09-14	AN
EARNINGS: Frontier Developments turns to loss; Poolbeg optimistic	23-09-13	AN

Chart RTW Biotech Opportunities Ltd

Duration

Period

More charts

Company Profile

RTW Biotech Opportunities Ltd is a Guernsey-based focused on identifying transformative assets with high growth potential across the biopharmaceutical and medical technology sectors. The Company invests in companies developing therapies and technologies that can significantly improve patients' lives. The Company seeks to achieve its investment objective by leveraging the Investment Manager's data driven pipeline of assets to invest in life sciences companies across various therapeutic categories and product types (including genetic medicines, biologics, traditional modalities, such as small molecule pharmaceuticals and antibodies, and medical devices). It intends to create a diversified portfolio of investments across a range of businesses, each pursuing the development of superior pharmacological or medical therapeutic assets to enhance the quality of life and/or extend patient life. The Company's portfolio is managed by RTW Investments, LP.

Sector

Closed End Funds

Calendar

2024-05-16 - Annual General Meeting

More about the company

Income Statement Evolution

More financial data

Sector Closed End Funds

	1st Jan change	Capi.
RTW BIOTECH OPPORTUNITIES LTD	-6.60%	504M
ARES CAPITAL CORPORATION	+3.74%	12.61B
PERSHING SQUARE HOLDINGS, LTD.	+5.50%	9.01B
FS KKR CAPITAL CORP.	-3.20%	5.41B
PIMCO DYNAMIC INCOME FUND	+5.63%	5.19B
SPROTT PHYSICAL URANIUM TRUST FUND	+2.44%	5.25B
SPROTT PHYSICAL SILVER TRUST	+14.36%	4.48B
SPROTT PHYSICAL GOLD AND SILVER TRUST	+16.67%	4.44B
MACQUARIE KOREA INFRASTRUCTURE FUND	+1.53%	4B
3I INFRASTRUCTURE PLC	+1.56%	3.75B